A characterization of the HIV population with limited/exhausted treatment options: a multicenter Belgian study

References

• Sciensano. Epidémiologie du sida et de l’infection à VIH en Belgique. 2021. [cited 2023 Jul 5]. Available from: https://www.sciensano.be/en/biblio/epidemiologie-du-sida-et-de linfection-a-vih-en-belgique-situation-au-31-decembre-2021
   Google Scholar
• Blanas DA, Nichols K, Bekele M, et al. HIV/AIDS among African-born residents in the United States. J Immigr Minor Health. 2013;15(4):718–724. doi: 10.1007/s10903-012-9691-6
   PubMed Web of Science ®Google Scholar
• Ross J, Akiyama MJ, Slawek D, et al. Undocumented African immigrants’ experiences of HIV testing and linkage to care. AIDS Patient Care STDS. 2019;33(7):336–341. doi: 10.1089/apc.2019.0036
   PubMed Web of Science ®Google Scholar
• Miller V, Staszewski S, Sabin C, et al. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy–induced suppression of human immunodeficiency virus load. J Infect Dis. 1999;180(2):530–533. doi: 10.1086/314890
   PubMed Web of Science ®Google Scholar
• Pinkevych M, Cromer D, Tolstrup M, et al. HIV reactivation from latency after treatment interruption occurs on average every 5-8 days—implications for HIV remission. PLOS Pathog. 2015;11(7):e1005000. doi: 10.1371/journal.ppat.1005000
   PubMed Web of Science ®Google Scholar
• Boulassel MR, Chomont N, Pai NP, et al. CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy. J Clin Virol. 2012;53(1):29–32. doi: 10.1016/j.jcv.2011.09.018
   PubMed Web of Science ®Google Scholar
• Priest J, Hulbert E, Gilliam BL, et al. Characterization of heavily treatment-experienced people with HIV and impact on healthcare resource utilization in US commercial and medicare advantage health plans. Open Forum Infect Dis. 2021;8(12):ofab562. doi: 10.1093/ofid/ofab562
   PubMed Web of Science ®Google Scholar
• Hsu RK, Fusco JS, Henegar CE, et al. Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes. BMC Infect Dis. 2023;23(1):91. doi: 10.1186/s12879-023-08038-w
   PubMed Web of Science ®Google Scholar
• Henegar C, Vannappagari V, Viswanathan S, et al. Identifying heavily treatment-experienced patients in a large administrative claims database. In: [Abstract MOPEB236] 10th IAS Conference on HIV Science; 2019 Jul 21–24; Mexico City, Mexico.
   Google Scholar
• Bajema KL, Nance RM, Delaney JAC, et al. Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options. AIDS. 2020;34(14):2051–2059. doi: 10.1097/QAD.0000000000002679
   PubMed Web of Science ®Google Scholar
• Lima VD, Harrigan PR, Senecal M, et al. Epidemiology of antiretroviral multiclass resistance. Am J Epidemiol. 2010;172(4):460–468. doi: 10.1093/aje/kwq101
   PubMed Web of Science ®Google Scholar
• Abraham AG, Lau B, Deeks S, et al. Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in North America. Am J Epidemiol. 2011;174(6):727–735. doi: 10.1093/aje/kwr141
   PubMed Web of Science ®Google Scholar
• Pillay D, Green H, Matthias R, et al. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis. 2005;192:967–973.
   PubMed Web of Science ®Google Scholar
• De Luca A, Dunn D, Zazzi M, et al. Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 2013;207(8):1216–1220. doi: 10.1093/infdis/jit017
   PubMed Web of Science ®Google Scholar
• Tamalet C, Fantini J, Tourres C, et al. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997– 2002) based on an analysis of over 7000 genotypes. AIDS. 2003;17(16):2383–2388. doi: 10.1097/00002030-200311070-00014
   PubMed Web of Science ®Google Scholar
• Audelin AM, Lohse N, Obel N, et al. The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999–2005. Antivir Ther. 2009;14(7):995–1000. doi: 10.3851/IMP1412
   PubMed Web of Science ®Google Scholar
• von Wyl V, Yerly S, Burgisser P, et al. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis. 2009;48:979–987. doi: 10.1086/597352
   PubMed Web of Science ®Google Scholar
• Gill VC, Lynch T, Ramazani S, et al. Reporting on the prevalence of antiretroviral drug resistance in a regional HIV population over 20 years: a word of caution. Antivir Ther. 2017;22(4):277–286. doi: 10.3851/IMP3105
   PubMed Web of Science ®Google Scholar
• Scherrer AU, von Wyl V, Yang WL, et al. Emergence of acquired HIV-1 drug resistance almost stopped in Switzerland: a 15-year prospective cohort analysis. Clin Infect Dis. 2016;62(10):1310–1317. doi: 10.1093/cid/ciw128
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Tashima KT, Smeaton LM, et al. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS clinical trials group A5241 (OPTIONS). J Infect Dis. 2020;221(9):1407–1415. doi: 10.1093/infdis/jiz281
   PubMed Web of Science ®Google Scholar